Cover Image
市場調查報告書

巨細胞病毒(HHV-5)感染疾病:開發中產品分析

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 229755
出版日期 內容資訊 英文 170 Pages
訂單完成後即時交付
價格
Back to Top
巨細胞病毒(HHV-5)感染疾病:開發中產品分析 Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018
出版日期: 2018年05月08日 內容資訊: 英文 170 Pages
簡介

巨細胞病毒(CMV)是皰疹病毒科的一種,是由病毒所引起的傳染性疾病。CMV會藉由唾液、尿液來傳染。常見的症狀有發燒、肺炎、體重減輕、聽障、神經病變、發育障礙等。容易罹患的危險因子除了直接接觸受感染的表面及生物之外,還有免疫力不足、先天性因素等。血液檢查及尿液檢查可以診斷出。可以服藥(抗病毒藥等)來降低症狀、或改善生活習慣等。

本報告提供巨細胞病毒(HHV-5)感染疾病的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

巨細胞病毒(HHV-5)感染疾病概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10411IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 9, 1, 20, 10 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 6, 7, 1, 5 and 3 molecules, respectively.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 5
  • Cytomegalovirus (HHV-5) Infections - Overview 6
  • Cytomegalovirus (HHV-5) Infections - Therapeutics Development 7
  • Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 21
  • Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 29
  • Cytomegalovirus (HHV-5) Infections - Drug Profiles 41
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects 148
  • Cytomegalovirus (HHV-5) Infections - Discontinued Products 152
  • Cytomegalovirus (HHV-5) Infections - Product Development Milestones 153
  • Appendix 161

List of Tables

  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2018 15
  • Number of Products under Development by Companies, H1 2018 17
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 18
  • Number of Products under Development by Universities/Institutes, H1 2018 20
  • Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018 21
  • Products under Development by Companies, H1 2018 22
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018 23
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018 24
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018 25
  • Products under Development by Universities/Institutes, H1 2018 26
  • Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018 28
  • Number of Products by Stage and Target, H1 2018 30
  • Number of Products by Stage and Mechanism of Action, H1 2018 32
  • Number of Products by Stage and Route of Administration, H1 2018 34
  • Number of Products by Stage and Molecule Type, H1 2018 36
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H1 2018 37
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AlfaSigma SpA, H1 2018 37
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H1 2018 38
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AvidBiotics Corp, H1 2018 38
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2018 38
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix Inc, H1 2018 39
  • Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Inc, H1 2018 40
  • Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax BV, H1 2018 40
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H1 2018 41
  • Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H1 2018 41
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H1 2018 41
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H1 2018 42
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea SA, H1 2018 42
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H1 2018 43
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H1 2018 43
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Moderna Therapeutics Inc, H1 2018 44
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2018 44
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H1 2018 44
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Qurient Co Ltd, H1 2018 45
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Shire Plc, H1 2018 45
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H1 2018 46
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H1 2018 46
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2018 47
  • Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H1 2018 47
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Vectorite Biomedical Inc, H1 2018 47
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Inc, H1 2018 48
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 156
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018 157
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 (Contd..2), H1 2018 158
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2018 (Contd..3), H1 2018 159
  • Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2018 160

List of Figures

  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2018 15
  • Number of Products under Development by Companies, H1 2018 16
  • Number of Products under Development by Universities/Institutes, H1 2018 19
  • Number of Products by Top 10 Targets, H1 2018 29
  • Number of Products by Stage and Top 10 Targets, H1 2018 29
  • Number of Products by Top 10 Mechanism of Actions, H1 2018 31
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 31
  • Number of Products by Routes of Administration, H1 2018 33
  • Number of Products by Stage and Routes of Administration, H1 2018 33
  • Number of Products by Top 10 Molecule Types, H1 2018 35
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018 35
Back to Top